Golimumab and Simponi
Type of Spiritual Experience
A description of the experience
Golimumab (CNTO 148) is a human monoclonal antibody which is used as an immunosuppressive drug and marketed under the brand name Simponi. Golimumab targets tumor necrosis factor alpha (TNF-alpha), a pro-inflammatory molecule and hence is a TNF inhibitor.
Golimumab was approved in Canada and the United States as a once monthly subcutaneous treatment for adults with moderately to severely active rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Golimumab has been approved in 2013 for use in adults with moderately to severely active ulcerative colitis.
The drug has also received an approval from European Medicines Agency (EMEA) for the use of golimumab as a treatment for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
On Jan, 15, 2017 15,387 people reported to have side effects when taking Simponi. Among them, 13 people (0.08%) have Hallucination
Time on Simponi when people have Hallucination :
|< 1 month||1 - 6 months||6 - 12 months||1 - 2 years||2 - 5 years||5 - 10 years||10+ years|
Gender of people who have Hallucination when taking Simponi :
Age of people who have Hallucination when taking Simponi :
The source of the experienceeHealthme
Concepts, symbols and science items
Activities and commonsteps